MasterSwitch Bio

Executive Summary

MasterSwitch Bio, founded in 2021 and based in Cambridge, MA, is a preclinical-stage biotechnology company developing next-generation switchable cell therapies and immunotherapies for cancer treatment. Its proprietary platform integrates molecular control systems that enable precise activation and deactivation of therapeutic cells, aiming to enhance safety and efficacy while reducing off-target toxicity. The technology addresses key limitations in cell therapy, such as cytokine release syndrome and on-target/off-tumor effects, by providing a dynamic ‘on-off’ switch. As a private company with no disclosed funding rounds or valuation, MasterSwitch Bio is in the early stages of platform validation and is expected to seek Series A financing to advance lead candidates toward the clinic. The company’s innovative approach has the potential to differentiate in the competitive cell therapy landscape, but its success hinges on preclinical proof-of-concept, manufacturing feasibility, and regulatory path.

Upcoming Catalysts (preview)

• Q3 2026Series A Financing Close80% success
• Q4 2026Preclinical Proof-of-Concept Data in Solid Tumors40% success
• Q2 2027First IND Filing for Lead Candidate30% success